From: Clinical efficacy and mechanism of mesenchymal stromal cells in treatment of COVID-19
Registration No | Country | Patients | Types of trials | Age(control/MSC) | Sex (M/F) | Number(control/MSC) | Methods | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ChiCTR2000031494 | China | Severe | A single-center open-label, individually randomized, standard treatment-controlled trial | 57.86 ± 15.79/61.00 ± 17.87 | 24/19 | 29/12 | Intravenous administration was used. Before the intravenous drip, the hUC-MSCs were suspended in 100 ml of normal saline, and the total number of transplanted cells was calculated as 2 × 106 cells/kg. The infusion was from the patients’ right cubital veins and lasted approximately 1 h (35 drops/min) | |||||||
NA | Iran | ARDS | A phase 1, two-center, open-label, single-arm trial | 53.80 ± 10.37 | 8/3 | 11 | The UC-MSCs were suspended in 100 ml normal saline with 5% w/w human serum albumin for each infusion. The PL-MSCs were suspended in 100 ml of normal saline supplemented with 2% w/w human serum albumin for each infusion. Three intravenous infusions (200 × 106 cells) every other day for a total of 600 × 106 cells. (UC-MSCs; 6 cases) or (PL-MSCs; 5 cases). The infusion time was approximately 30–45 min at a speed of approximately 50 drops/min | |||||||
NCT04252118 | China | Moderate, severe | A parallel assigned controlled, non-randomized, phase 1 clinical trial |  | 11/7 | 9/9 | Received three cycles of intravenous infusion of allogeneic UC-MSCs (3 × 107cells each infusion) on days 0, 3, and 6. The total volume of the UC-MSCs infusion was 60 ml | |||||||
NCT04288102 | China | Severe | A randomized, double-blind, placebo-controlled phase 2 trial | 59.94/60.72 | 56/44 | 35/65 | The treatment dose was 4.0 × 107 cells for each procedure, and three procedures were carried out for each patient on day 0, 3, and 6 after randomization. Infusion was started with a standard blood filter tubing set with a pore size of 170 μm. Under electrocardiographic monitoring, the cell product was infused by gravity within 60 min | |||||||
NCT04392778 | Turkey | Critical ill | A prospective double-controlled trial |  | 19/11 | 10/10/10 | Three consecutive doses on treatment days 0, 3, and 6, (as 3 × 106cells/kg, intravenously) | |||||||
ChiCTR2000029606 | China | Severe, critically ill | A multicenter, open-label, nonrandomized, and parallel controlled phase I clinical trial | 61.11/58.31 | 30/14 | 18/26 | Menstrual blood-derived MSC were administered as three infusions totaling 9 × 107MSCs every other day (day 1, day 3, and day 5). Each infusion contained 3 × 107cells resuspended in 500 mL saline solution and was performed at a speed of 30–40 drops/min for about 15 min, followed by a speed of 100–120 drops/min for 2 h to retain MSC vitality | |||||||
NCT04355728 | USA | ARDS | A double-blind, phase 1/2a, randomized controlled trial | 58.83 ± 11.61/58.58 ± 15.93 | 13/11 | 12/12 | Two intravenous infusions of 100 ± 20 × 106UC-MSCs each, in 50 mL vehicle solution containing human serum albumin and heparin, infused over 10 ± 5 min, at days 0 and 3 |